読み込み中
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
終値時点
$2.00
+$0.01 · +0.50%
時間外
$2.00
$0.00 · 0.00%
10月9日 18:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $2.00
52週レンジ
現在 $2.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
67
割安
センチメント
41
まちまち
リスク
67
高リスク
モメンタム
68
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $2.00
52週レンジ
現在 $2.00
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3090.9万 USD | 2260.2万 USD | 3415.5万 USD | 1922.8万 USD | 131.9万 USD |
| 売上原価 | 333.2万 USD | — | — | — | — |
| 粗利益 | 2757.7万 USD | 2260.2万 USD | 3415.5万 USD | 1922.8万 USD | 131.9万 USD |
| 研究開発 | 8546.6万 USD | 9452.8万 USD | 1.1億 USD | 1.06億 USD | 8032.5万 USD |
| 販売・一般管理 | 2755万 USD | 2835.9万 USD | 3237.2万 USD | 3074.7万 USD | 2172.8万 USD |
| 営業費用 | 1.1億 USD | 1.25億 USD | 1.42億 USD | 1.36億 USD | 1.02億 USD |
| 受取利息 | 874.5万 USD | 1190万 USD | 1087.5万 USD | 567.5万 USD | 5.9万 USD |
| 支払利息 | — | — | — | — | 190.6万 USD |
| 減価償却費と償却費 | 333.2万 USD | 312万 USD | 345.1万 USD | 332.1万 USD | 322.7万 USD |
| 営業利益 | −8210.7万 USD | −1.03億 USD | −1.08億 USD | −1.17億 USD | −1.01億 USD |
| 純利益 | −7428.3万 USD | −8662万 USD | −9842.6万 USD | −1.09億 USD | −1.01億 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$4.25
上昇余地（112.50%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI642.12万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF245.85万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 ETFIWM182.32万0.00%776.97億 USD0.19%$278.94+0.49%
Vanguard Russell 2000 ETFVTWO120.15万0.01%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO67.9万0.00%140.44億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB48.43万0.00%104.14億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 Growth ETFVTWG22.85万0.01%17億 USD0.06%$260.49+0.91%
iShares Micro-Cap ETFIWC22.72万0.02%13.19億 USD0.60%$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 Growth ETFVTWGiShares Micro-Cap ETFIWCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
